Search Results

Genetown

Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

Ventus Therapeutics, Inc announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference.

April 8, 2024

·

2 min read

Business

Cellular Origins, a TTP Company, Appoints Peter Crossley as Chief Operating Officer

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, announced the appointment of Peter Crossley as Chief Operating Officer.

January 25, 2024

·

2 min read

Drug Development

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).

May 3, 2024

·

6 min read

Press Releases

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

October 31, 2024

·

3 min read

Drug Development

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor

Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.

April 17, 2024

·

7 min read

Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference

Ventus Therapeutics announced today that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel 2023 Healthcare Conference in New York.

November 9, 2023

·

2 min read

Drug Development

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

Ventus Therapeutics announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.

January 3, 2024

·

4 min read

Ventus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ventus Therapeutics announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PST.

January 2, 2024

·

2 min read

Business

TTP Introduces Cellular Origins, a TTP Company Focussed on Delivering Scalable Manufacture of Cell and Gene Therapies

TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company.

January 17, 2023

·

4 min read

Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023

Ventus Therapeutics announced that it has been named a “Fierce 15” company in Fierce Biotech’s 2023 annual report featuring the most innovative and promising biotechnology companies in the industry.

August 28, 2023

·

4 min read